Skip to main content
Erschienen in: Medical Oncology 6/2014

01.06.2014 | Original Paper

Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia

verfasst von: Nina Petrović, Vesna Mandušić, Bogomir Dimitrijević, Jelena Roganović, Silvana Lukić, Lidija Todorović, Boban Stanojević

Erschienen in: Medical Oncology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs play essential role in breast carcinoma progression and invasion. Our principal goals were to assess clinicopathological and prognostic correlations of microRNA-21 (miR-21) expression levels in a group of 39 Serbian breast cancer patients with invasive lobular (ILC), ductal (IDC), or mixed (ILC–IDC) breast carcinomas and in order to discover the role of miR-21 in potential novel form of stratification of the patients with different estrogen receptor (ER) and progesterone receptor (PR) status. MiR-21 expression levels were measured by stem-loop real-time RT-PCR using TaqMan technology. ER, PR, human epidermal growth factor 2 receptor (Her-2), and proliferative index (Ki-67) were evaluated by immunohistochemistry. MiR-21 levels do not vary among ILC, IDC, and ILC–IDC subgroups. MiR-21 expression levels varied significantly in the age, tumor size, Ki-67, and different grade (p = 0.030, p = 0.036, p = 0.027 and p = 0.032, respectively) subgroups. ER+ and PR+ showed higher miR-21 levels than their negative receptor status paired groups ER− and PR− with p = 0.012 and p = 0.018, respectively. MiR-21 positively correlated with ER and PR status (p = 0.018, ρ = 0.379 and p = 0.034, ρ = 0.345, respectively). Our findings suggest that miR-21 emulates transitional form of expression and that the levels of expression might be useful for stratification of the patients with different receptor status with the purpose to seek for new therapy approaches especially for the patients with the lack of response to conventional endocrine therapy.
Literatur
3.
Zurück zum Zitat Huang G-L, Zhang X-H, Guo G-L, Huang K-T, Yang K-Y, Shen X, You J, Hu X-Q. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009. doi:10.3892/or_00000270. Huang G-L, Zhang X-H, Guo G-L, Huang K-T, Yang K-Y, Shen X, You J, Hu X-Q. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncol Rep. 2009. doi:10.​3892/​or_​00000270.
6.
Zurück zum Zitat Qi L, Bart J, Tan L, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H, Berg A. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9(1):163. doi:10.1186/1471-2407-9-163.PubMedCentralPubMedCrossRef Qi L, Bart J, Tan L, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H, Berg A. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009;9(1):163. doi:10.​1186/​1471-2407-9-163.PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999;49:1067–77. doi:10.1186/bcr1285.PubMedCrossRef Yoshinaga H, Matsuhashi S, Fujiyama C, Masaki Z. Novel human PDCD4 (H731) gene expressed in proliferative cells is expressed in the small duct epithelial cells of the breast as revealed by an anti-H731 antibody. Pathol Int. 1999;49:1067–77. doi:10.​1186/​bcr1285.PubMedCrossRef
9.
Zurück zum Zitat Span PN, Lindberg RLP, Manders P, Tjan-Heijnen VCG, Heuvel JJTM, Beex LVAM, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol. 2004;202(4):395–402. doi:10.1002/path.1528.PubMedCrossRef Span PN, Lindberg RLP, Manders P, Tjan-Heijnen VCG, Heuvel JJTM, Beex LVAM, et al. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol. 2004;202(4):395–402. doi:10.​1002/​path.​1528.PubMedCrossRef
10.
Zurück zum Zitat Mylona E, Magkou C, Giannopoulou I, Agrogiannis G, Markaki S, Keramopoulos A, Nakopoulou L. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome. Breast Cancer Res. 2006;8(5):R57. doi:10.1186/bcr1607.PubMedCentralPubMedCrossRef Mylona E, Magkou C, Giannopoulou I, Agrogiannis G, Markaki S, Keramopoulos A, Nakopoulou L. Expression of tissue inhibitor of matrix metalloproteinases (TIMP)-3 protein in invasive breast carcinoma: Relation to tumor phenotype and clinical outcome. Breast Cancer Res. 2006;8(5):R57. doi:10.​1186/​bcr1607.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Li J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, Ma Y, Li D. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Sur Oncol. 2013;2013:1–7. doi:10.1155/2013/875078.CrossRef Li J, Zhang Y, Zhang W, Jia S, Tian R, Kang Y, Ma Y, Li D. Genetic heterogeneity of breast cancer metastasis may be related to miR-21 regulation of TIMP-3 in translation. Int J Sur Oncol. 2013;2013:1–7. doi:10.​1155/​2013/​875078.CrossRef
13.
Zurück zum Zitat Lopez-Camarillo C, Fonseca-Sánchez MA, Flores-Pérez A, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, et al. Functional roles of microRNAs in cancer: microRNomes and oncomiRs connection. In: Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, Perez Plasencia C, Fuentes-Mera L, et al., editors. Oncogenomics and cancer proteomics—novel approaches in biomarkers discovery and therapeutic targets in cancer. InTech, p. 72–89, 2013; 9(1):53–9. doi:10.1111/j.1743-7563.2012.01548.x. Lopez-Camarillo C, Fonseca-Sánchez MA, Flores-Pérez A, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, et al. Functional roles of microRNAs in cancer: microRNomes and oncomiRs connection. In: Lopez-Camarillo C, Marchat LA, Arechaga-Ocampo E, Azuara-Liceaga E, Perez Plasencia C, Fuentes-Mera L, et al., editors. Oncogenomics and cancer proteomics—novel approaches in biomarkers discovery and therapeutic targets in cancer. InTech, p. 72–89, 2013; 9(1):53–9. doi:10.​1111/​j.​1743-7563.​2012.​01548.​x.
14.
Zurück zum Zitat Rask L, Balslev EVA, JØRgensen S, Eriksen J, Flyger H, MØLler S, HØGdall E, Litman T, Schnack Nielsen B. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. Apmis. 2011;119(10):663–73. doi:10.1111/j.1600-0463.2011.02782.x.PubMedCrossRef Rask L, Balslev EVA, JØRgensen S, Eriksen J, Flyger H, MØLler S, HØGdall E, Litman T, Schnack Nielsen B. High expression of miR-21 in tumor stroma correlates with increased cancer cell proliferation in human breast cancer. Apmis. 2011;119(10):663–73. doi:10.​1111/​j.​1600-0463.​2011.​02782.​x.PubMedCrossRef
16.
Zurück zum Zitat Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199–208.PubMedCrossRef Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115(2):199–208.PubMedCrossRef
17.
Zurück zum Zitat Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11(3):R27. doi:10.1186/bcr2257.PubMedCentralPubMedCrossRef Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res. 2009;11(3):R27. doi:10.​1186/​bcr2257.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Verkooijen HM, Fioretta Gr, Vlastos G, Morabia A, Schubert H, Sappino A-P, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int Cancer. 2003;104(6):778–81. doi:10.1002/ijc.11032.CrossRef Verkooijen HM, Fioretta Gr, Vlastos G, Morabia A, Schubert H, Sappino A-P, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int Cancer. 2003;104(6):778–81. doi:10.​1002/​ijc.​11032.CrossRef
19.
Zurück zum Zitat Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, et al. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. Med Oncol. 2014;31(3):867. doi:10.1007/s12032-014-0867-x.PubMedCrossRef Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, et al. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. Med Oncol. 2014;31(3):867. doi:10.​1007/​s12032-014-0867-x.PubMedCrossRef
20.
Zurück zum Zitat Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007;67(21):10582–91.PubMedCrossRef Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, Horwitz KB. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res. 2007;67(21):10582–91.PubMedCrossRef
21.
Zurück zum Zitat Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7(5):R753. doi:10.1186/bcr1285.PubMedCentralPubMedCrossRef Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H. Phosphorylation of estrogen receptor α serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res. 2005;7(5):R753. doi:10.​1186/​bcr1285.PubMedCentralPubMedCrossRef
22.
25.
Zurück zum Zitat Kim YJ, Hwang SJ, Bae YC, Jung JS. miR-21 regulates adipogenic differentiation through the modulation of TGF-β signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells. 2009;27(12):3093–102. doi:10.1002/stem.235.PubMed Kim YJ, Hwang SJ, Bae YC, Jung JS. miR-21 regulates adipogenic differentiation through the modulation of TGF-β signaling in mesenchymal stem cells derived from human adipose tissue. Stem Cells. 2009;27(12):3093–102. doi:10.​1002/​stem.​235.PubMed
26.
Zurück zum Zitat Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2008;117(1):131–40. doi:10.1007/s10549-008-0219-7.PubMedCrossRef Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1. Breast Cancer Res Treat. 2008;117(1):131–40. doi:10.​1007/​s10549-008-0219-7.PubMedCrossRef
27.
28.
Zurück zum Zitat Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70. doi:10.1158/0008-5472.CAN-05-1783.PubMedCrossRef Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70. doi:10.​1158/​0008-5472.​CAN-05-1783.PubMedCrossRef
30.
Zurück zum Zitat Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5(1):24. doi:10.1186/1476-4598-5-24.PubMedCentralPubMedCrossRef Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006;5(1):24. doi:10.​1186/​1476-4598-5-24.PubMedCentralPubMedCrossRef
31.
Zurück zum Zitat Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Nat Cancer Inst. 2005;97(17):1254–61. doi:10.1093/jnci/dji249.PubMedCrossRef Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Nat Cancer Inst. 2005;97(17):1254–61. doi:10.​1093/​jnci/​dji249.PubMedCrossRef
Metadaten
Titel
Higher miR-21 expression in invasive breast carcinomas is associated with positive estrogen and progesterone receptor status in patients from Serbia
verfasst von
Nina Petrović
Vesna Mandušić
Bogomir Dimitrijević
Jelena Roganović
Silvana Lukić
Lidija Todorović
Boban Stanojević
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 6/2014
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0977-5

Weitere Artikel der Ausgabe 6/2014

Medical Oncology 6/2014 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.